Trends in Mode of Hysterectomy After the U.S. Food and Drug Administration Power Morcellation Advisory
- PMID: 28486371
- DOI: 10.1097/AOG.0000000000002058
Trends in Mode of Hysterectomy After the U.S. Food and Drug Administration Power Morcellation Advisory
Abstract
Objective: To evaluate the trends in mode of surgery for benign hysterectomy after the 2014 U.S. Food and Drug Administration (FDA) morcellation guidelines.
Methods: This is a retrospective review of all patients who underwent a hysterectomy for benign indications, specifically for leiomyomas, at Brigham and Women's Hospital from 2013 to 2015. The rates of abdominal, vaginal, laparoscopic, and robotic-assisted laparoscopic hysterectomy as well as the perioperative outcomes were compared over the study period. Analysis was performed using multivariable linear, multinomial, and logistic regression. Regression models were adjusted for potential confounders.
Results: From 2013 to 2015, 1,530 patients underwent a hysterectomy for benign indications and 639 patients underwent the procedure for the indication of uterine leiomyomas; there was a decrease in the number of hysterectomy cases in the later years. Focusing on the patients with leiomyomas alone, there was a 40-60% decreased odds of a minimally invasive procedure in 2014 or 2015 compared with 2013 [adjusted odds ratio (OR) 0.53 (0.29-0.97) in 2014 and adjusted OR 0.40 (0.22-0.74) in 2015, P=.003]. A 24% decrease in the supracervical approach to hysterectomy was also noted. Despite these trends, the majority of cases in each year were still performed in a minimally invasive fashion. The factor most strongly associated with undergoing a minimally invasive hysterectomy was having a fellowship-trained surgeon perform the procedure [adjusted OR 6.80 (3.65-12.7), P<.001]. There was no significant difference between the year of surgery and occurrence of intraoperative complications or reoperation.
Conclusion: Although key perioperative outcomes remained similar, the overall rate of minimally invasive surgery declined at our institution after the FDA's recommendations. With changing practice patterns and vigilance surrounding power morcellation, gynecologic surgeons may still offer patients minimally invasive procedures with all of the accompanying advantages.
Similar articles
-
Practice Patterns and Complications of Benign Hysterectomy Following the FDA Statement Warning Against the Use of Power Morcellation.JAMA Surg. 2018 Jun 20;153(6):e180141. doi: 10.1001/jamasurg.2018.0141. Epub 2018 Jun 20. JAMA Surg. 2018. PMID: 29641835 Free PMC article.
-
Practice patterns and postoperative complications before and after US Food and Drug Administration safety communication on power morcellation.Am J Obstet Gynecol. 2016 Jan;214(1):98.e1-98.e13. doi: 10.1016/j.ajog.2015.08.047. Epub 2015 Aug 24. Am J Obstet Gynecol. 2016. PMID: 26314519
-
Association of the U.S. Food and Drug Administration Morcellation Warning With Rates of Minimally Invasive Hysterectomy and Myomectomy.Obstet Gynecol. 2015 Dec;126(6):1174-1180. doi: 10.1097/AOG.0000000000001111. Obstet Gynecol. 2015. PMID: 26595561
-
Current Issues with Hysterectomy.Obstet Gynecol Clin North Am. 2016 Sep;43(3):591-601. doi: 10.1016/j.ogc.2016.04.012. Obstet Gynecol Clin North Am. 2016. PMID: 27521886 Review.
-
Laparoscopic myomectomy and morcellation: A review of techniques, outcomes, and practice guidelines.Best Pract Res Clin Obstet Gynaecol. 2018 Jan;46:99-112. doi: 10.1016/j.bpobgyn.2017.09.012. Epub 2017 Sep 29. Best Pract Res Clin Obstet Gynaecol. 2018. PMID: 29078975 Review.
Cited by
-
Currently Available Treatment Modalities for Uterine Fibroids.Medicina (Kaunas). 2024 May 26;60(6):868. doi: 10.3390/medicina60060868. Medicina (Kaunas). 2024. PMID: 38929485 Free PMC article. Review.
-
Potential Markers to Differentiate Uterine Leiomyosarcomas from Leiomyomas.Int J Med Sci. 2024 May 13;21(7):1227-1240. doi: 10.7150/ijms.93464. eCollection 2024. Int J Med Sci. 2024. PMID: 38818470 Free PMC article. Review.
-
An intrauterine cavity morcellator: A novel approach to high volume uterus morcellation. Ex-vivo study.PLoS One. 2023 Mar 17;18(3):e0282149. doi: 10.1371/journal.pone.0282149. eCollection 2023. PLoS One. 2023. PMID: 36930660 Free PMC article.
-
Fibroid Removal after Myomectomy: An Overview on the Problems of Power Morcellation.Healthcare (Basel). 2022 Oct 19;10(10):2087. doi: 10.3390/healthcare10102087. Healthcare (Basel). 2022. PMID: 36292534 Free PMC article. Review.
-
Risk Factors Associated with Perineal and Vaginal Lacerations and Vaginal Removal in Total Laparoscopic Hysterectomy.Gynecol Minim Invasive Ther. 2022 Aug 5;11(3):150-154. doi: 10.4103/gmit.gmit_118_21. eCollection 2022 Jul-Sep. Gynecol Minim Invasive Ther. 2022. PMID: 36158298 Free PMC article.
References
-
- Siedhoff MT, Wheeler SB, Rutstein SE, Geller EJ, Doll KM, Wu JM, et al. Laparoscopic hysterectomy with morcellation vs abdominal hysterectomy for presumed fibroid tumors in premenopausal women: a decision analysis. Am J Obstet Gynecol 2015;212:591.e1–8.
-
- Food and Drug Administration. Laparoscopic uterine power morcellation in hysterectomy and myomectomy: FDA safety communication. Available at: http://www.fda.gov/MedicalDevices/Safety/AlertsandNotices/ucm393576.htm. Retrieved October 4, 2016.
-
- Food and Drug Administration. UPDATED laparoscopic uterine power morcellation in hysterectomy and myomectomy: FDA safety communication. Available at: http://www.fda.gov/MedicalDevices/Safety/AlertsandNotices/ucm424443.htm. Retrieved October 4, 2016.
-
- Harris JA, Swenson CW, Uppal S, Kamdar N, Mahnert N, As-Sanie S, et al. Practice patterns and postoperative complications before and after US Food and Drug Administration safety communication on power morcellation. Am J Obstet Gynecol 2016;214:98.e1–e13.
-
- Wright JD, Chen L, Burke WM, Hou JY, Tergas AI, Ananth CV, et al. Trends in use and outcomes of women undergoing hysterectomy with electric power morcellation. JAMA 2016;316:877–8.
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
